Category: Addiction treatment

According to the National Institute on Drug Abuse (NIDA), methadone has been used for over 50 years to treat opioid use disorder. This liquid formulation plays a critical role in treatment, and understanding what is the use of methadone syrup is essential for patients and caregivers.

According to the National Institute on Drug Abuse (NIDA), methadone and buprenorphine are equally effective medications for treating opioid use disorder (OUD). In the context of OUD treatment, the drug most pharmacologically comparable and functionally closest to methadone is buprenorphine.

Naltrexone is a medication-assisted treatment for opioid and alcohol use disorders, but combining it with certain substances can have severe, and even life-threatening, consequences. Therefore, it is critical to understand **what you should not mix with naltrexone** to ensure treatment is safe and effective.

According to the Centers for Disease Control and Prevention (CDC), millions of Americans are affected by opioid use disorder (OUD), a condition that medication-assisted treatment (MAT) can effectively manage. A crucial part of this treatment is understanding **who is a good candidate for buprenorphine** and what criteria determine eligibility for this life-changing medication.

Since the federal X-waiver requirement was eliminated in 2023, more healthcare professionals than ever are able to prescribe Suboxone for opioid use disorder (OUD). As a result, finding out **what kind of doctors prescribe Suboxone** is a much broader search than in the past, encompassing primary care physicians, specialists, and telehealth providers.

Medication-assisted treatment (MAT) is a proven, evidence-based method for treating opioid use disorder (OUD), yet a 2021 national survey revealed only 22% of people diagnosed with OUD were prescribed one of the FDA-approved medications. For individuals seeking alternatives or requiring different treatment modalities, it is crucial to understand what drugs are similar to buprenorphine and how they function to manage withdrawal, cravings, or chronic pain.

Sublocade, an injectable form of buprenorphine, provides a steady release of medication to manage opioid use disorder (OUD) [1.6.1]. The pivotal question for some patients and clinicians is: **can Sublocade be given every 3 weeks** to optimize treatment?

Due to its extended-release formulation, Sublocade creates a natural, gradual tapering effect after the last injection, releasing therapeutic levels of buprenorphine for months. This unique pharmacological profile significantly influences how you manage patients who discontinue Sublocade, necessitating a focus on long-term monitoring and robust supportive care.

In 2023, there were over 15 million buprenorphine prescriptions dispensed in the U.S. for opioid use disorder (OUD) [1.6.6]. This raises a critical question for patients and caregivers: **What is the antidote for Sublocade?** The answer lies in understanding its unique pharmacology.

Sublocade, a buprenorphine injection, has a boxed warning from the FDA due to the risk of serious harm or death if administered intravenously [1.3.1, 1.3.2, 1.3.3]. So, what happens if Sublocade is injected wrong, and why are the consequences so severe?